Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Lilly begins real-world Covid-19 study of bamlanivimab in New Mexico to assess outcomes in high-risk patients Eli Lilly begins a real-world Covid-19 study of bamlanivimab in New Mexico. Find out how mobile clinics aim to reduce hospitalizations in high-risk patients. bypharmanewsdailyDecember 19, 2020